Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.31 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567156 | 0.77 | MT-CO2 (0.34) | TLR4MT-CO2ALOX5 | |
| SCHEMBL2450408 | 0.74 | SMN1; SMN2 (0.36) | LMNA | |
| SCHEMBL2446215 | 0.73 | TNKS2 (0.34) | TLR4 | |
| SCHEMBL17844887 | 0.73 | TLR4 (0.40) | TLR4GLA | |
| SCHEMBL2446668 | 0.73 | KMT2A (0.39) | LMNA | |
| SCHEMBL5770917 | 0.73 | MCL1 (0.43) | TLR4LMNAALKBH5SUCNR1EGLN1 | |
| SCHEMBL16503645 | 0.72 | TLR4 (0.36) | TLR4MT-CO2ALOX5 | |
| SCHEMBL2718691 | 0.71 | MCL1 (0.50) | TLR4LMNA | |
| SCHEMBL10339687 | 0.70 | MCL1 (0.49) | TLR4LMNA | |
| SCHEMBL5773706 | 0.70 | MCL1 (0.49) | TLR4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0885883-B1 | FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-6187774-B1 | N-PIPERAZINYLALKYLINDAZOLE DERIVATIVES; PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0885883-A1 | FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |